ZYZejun Yan

Zejun Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zejun Yan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laparoscopic Resection Combined With Aspiration for Central Renal Angiomyolipoma:Preliminary Outcomes of a Novel Surgical Technique

    by Dong Zhang, Yue Cheng, Junhui Jiang, Zhaohu Jiang, Cheng Zhou, Zejun Yan

    BackgroundThe purpose of this article was to explore the safety and efficacy of laparoscopic resection combined with aspiration in a selected cohort of 17 patients with central renal angiomyolipoma(RAML). Methods17 patients diagnosed with central RAML by the pathological report and CT/MRI were enrolled in our center from August 2015 to November 2019. The indication for surgery was tumor size more than 4cm or symptomatic tumor such as hemorrhage, backache or hematuria. The main endpoint included operative time, warm ischemia time(WIT), intraoperative blood loss, postoperative hospital time, complications and renal function.ResultsThe average age was 45.3±4.8 years, 12 patients were women, 5 patients were men. Of all cases,10 underwent peritoneal laparoscopic resection and 7 underwent retroperitoneal surgery. All operations were performed successfully without conversion to open surgery. One patient experienced collecting system injury managed by 3-0 barbed self-retaining suture. The average size of the tumors was (6.9±2.3)cm. The average operation time,blood loss, WIT, and postoperative hospital time were (105.3±19.5)min, (145.8±35.7)ml, (25.6±4.2)min and 5-7 days, respectively. No complications happened in the postoperative period, and there were no local recurrence and distant metastases at a 28.5 month follow-up period. Pre-operative and post-operative serum creatinine(SCr) were (67.6±15.8)μmol/L and (65.4±16.8)μmol/L, indicating no significant renal function drop was found. Similarly, no significant difference was found in terms of preoperative and postoperative diseased renal glomerular filtration rate(GFR)value. The main limitation included the sample size and short follow-up time.ConclusionsThe results of this study supported that laparoscopic resection combined with aspiration was a feasible, safe and effective procedure in the treatment of RAML, especially for the large central RAML which is closely related to the collection system and renal blood vessels.

  • Open Access

    Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis

    by Dong Zhang, Lifeng Yao, Sui Yu, Yue Cheng, Junhui Jiang, Qi Ma, Zejun Yan

    Background: The purpose of this meta-analysis is to compare the safety and efficacy of en bloc transurethral resection of bladder tumor (EBRT) versus conventional transurethral resection of bladder tumor (CTURBT). Methods: We performed a meta-analysis of relevant articles through November 2019 using PubMed, Embase, and Cochrane Central Register to compare the safety and efficacy of EBRT versus CTURBT. The main endpoint included the operation time (OT), hospitalization time (HT), catheterization time (AT), perioperative period complications, bladder detrusor muscle found in the specimen, the residual tumor on the base, the ratio of the same site recurrence, and 12/24/36-month recurrence rate. Cochrane Collaboration’s Revman software, version 5.3, was used for statistical analysis. Results: A total of 19 studies with 2651 patients were included, 1369 underwent EBRT and 1282 underwent CTURBT. Patients treated with EBRT had a significantly lower AT, HT, obturator nerve reflex, bladder perforation, bladder irritation, postoperative complications, and 24-month recurrence rate than those who underwent CTURBT. While no significant difference was found in terms of OT, the ratio of bladder detrusor muscle found in the specimen, the residual tumor on the base, 12-month recurrence rate, 36-month recurrence rate, and the ratio of the same site recurrence. In mitomycin subgroup, EBRT was superior to CTURBT in terms of 12/24-month recurrence rate. Similarly, in the prospective subgroup and retrospective subgroup, EBRT had a lower 24-month recurrence rate than CTURBT. However, no significant difference was found in the low, intermediate, and high-risk group in the light of 12–36-month recurrence rate. Conclusions: Based on the included 19 articles, EBRT had a significantly lower AT, HT, intraoperative and postoperative complications, and 24-month recurrence rate than those treated with CTURBT. Well-designed randomized controlled trials were needed to reevaluate these outcomes. Trial registration: This meta-analysis was reported in agreement with the PRISMA statement and was registered on PROSPERO 2019 CRD42019121673.